Pharmaceutical Products of the Future: 50-Company Biopharma and Traditional Pipeline Analysis to 2016

August 2012 | 220 pages | ID: PD05B68E42AEN
Kalorama Information

Abstracts

What Will the Pharma Industry Look Like in 5 Years?

There are an estimated 724 projects in development from the top 50 pharmaceutical companies. Together, they have the potential to add billions in value to the current pharmaceutical market in the next five years. What types of drugs are companies developing and what will be the impact of these products on the marketplace and key competitors? In this report, Kalorama Information has analyzed the late-stage R&D pipeline of the 50 top companies in pharmaceuticals - the companies that produce the lion's share of industry revenues.

Coverage of the 50 Leading Companies

This report takes a look at the pipeline of the following companies. The top companies include pharmaceutical companies that are considered to be the top 50 companies worldwide in terms of generated revenues, these include:

• Abbott Laboratories
• Actelion
• Allergan
• Amgen
• Astellas
• AstraZeneca
• Baxter International
• Bayer
• Biogen IDEC
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Celgene Corp.
• CSL
• Daiichi Sankyo
• Dainippon Sumitomo
• Eisai
• Eli Lilly & Co.
• Forest
• Gilead Sciences
• GlaxoSmithKline
• Grifols SA
• Hospira
• Johnson & Johnson
• Kyowa Kirin
• Lundbeck
• Menarini
• Merck
• Merck KGaA
• Mitsubishi Tanabe Pharma
• Mylan
• Novartis
• Novo Nordisk
• Ono Pharmaceutical Co.
• Otsuka Pharmaceutical
• Pfizer
• Purdue Pharma
• Reckitt Benckiser
• Roche
• Sanofi
• Santen Pharmaceuticals
• Servier
• Shionogi
• Shire
• Taisho Pharmacueitcal
• Takeda
• TEVA
• UCB
• Valeant Pharmaceuticals
• Warner Chilcott
• Watson

While the report looks at the entire pipeline to 2015, a key focus of the report is the increasing role of biopharmaceutical products. The growing interest in biotechnology development has transitioned the pharmaceutical industry to biopharmaceuticals in less than a decade. Companies such as Pfizer, Merck and Novartis have been unable to ignore the benefits of investing in biotechnology and have focused on a pipeline in this direction through strategic acquisitions and partnerships with biotech companies and/or through their own in-house research efforts.

Pipeline Analysis, Key Trends, Market Forecasts

This Kalorama Information market research report captures these trends, extracting sales for all pharmaceutical and biopharmaceutical products (excluding prophylactic vaccines and OTC products) and providing estimates and forecasts of the world biopharma market.

As part of its coverage, the report provides the following:

• Company Analysis
• Pipeline Snapshot: Top 20 Companies
• Market Trends and Value
• Evaluating Changes in 2011 Market Value
• The Traditional Pharmaceutical Market
• Biotechnology Market Facts and Forecast

For the purpose of this study, Kalorama Information has extracted sales for human pharmaceutical and biopharmaceutical products; consumer pharmaceuticals and products; diagnostics; devices; chemicals; agriculture; and animal health. These are areas where many of these companies also compete with significant market shares.

Contents

CHAPTER ONE: EXECUTIVE SUMMARY

Introduction
Scope and Methodology
Potential Market Opportunity
Issues and Trends Affecting Market
Leading Companies

CHAPTER TWO: INTRODUCTION

Global Pharmaceutical Market
Pharmaceutical Research & Development Overview
Expanded Options in Treating Diseases

CHAPTER THREE: ISSUES AND TRENDS

Biotechnology Drug Development
Orphan Drugs
Fast Track Drug Status
Other Accelerated Methods for Drug Approval
Pharmaceutical Regulatory Exclusivity
Pediatric Extensions
Biopharmaceutical Industry—Biosimilar (Biogeneric) Development and Exclusivity Legislation
Aging Population
Mergers, Acquisitions, and Collaborations
Contributors To R&D Success
R&D Spending
The Role of Contract Research Organization
Sustainability in a Changing Pharmaceutical Industry

CHAPTER FOUR: WORLDWIDE PHARMACEUTICAL INDUSTRY LEADERS

Introduction
Pfizer, Inc.
  Overview
  Financial Performance and Investments
  Late Stage Pipeline
Merck & Co., Inc.
  Overview
  Financial Performance and Investments
  Late Stage Pipeline
Novartis
  Overview
  Financial Performance and Investments
  Late Stage Pipeline
Sanofi
  Overview
  Financial Performance and Investments
  Late Stage Pipeline
Roche Ltd.
  Overview
  Financial Performance and Investments
  Late Stage Pipeline
GlaxoSmithKline plc
  Overview
  Financial Performance and Investments
  Late Stage Pipeline
AstraZeneca plc
  Overview
  Financial Performance and Investments
  Late Stage Pipeline
Johnson & Johnson
  Overview
  Financial Performance and Investments
  Late Stage Pipeline
Eli Lilly & Company
  Overview
  Financial Performance and Investments
  Late Stage Pipeline
Abbott Laboratories
  Overview
  Financial Performance and Investments
  Late Stage Pipeline
Bristol-Myers Squibb Company
  Overview
  Financial Performance and Investments
  Late Stage Pipeline
Takeda Pharmaceutical Co., Ltd.
  Overview
  Financial Performance and Investments
  Late Stage Pipeline
TEVA Pharmaceutical Industries, Ltd.
  Overview
  Financial Performance and Investments
  Late Stage Pipeline
Amgen, Inc.
  Overview
  Financial Performance and Investments
  Late Stage Pipeline
Boehringer Ingelheim GmbH
  Overview
  Financial Performance and Investments
  Late Stage Pipeline
Bayer AG
  Overview
  Financial Performance and Investments
  Late Stage Pipeline
Novo Nordis
  Overview
  Financial Performance and Investments
  Late Stage Pipeline
Astellas
  Overview
  Financial Performance and Investments
  Late Stage Pipeline
Daiichi Sankyo
  Overview
  Financial Performance and Investmen
  Late Stage Pipeline
Otsuka
  Overview
  Financial Performance and Investments
  Late Stage Pipeline

CHAPTER FIVE: COMPANIES OF INTEREST

Introduction
Merck KGaA
  Late Stage Pipeline
Gilead Sciences
  Late Stage Pipeline
Eisai
  Late Stage Pipeline
Mylan
  Pipeline
Baxter International
  Pipeline
Servier, Les Laboratories
  Pipeline
Celgene Corporation
  Late Stage Pipeline
Mitsubishi Tanabe
  Late Stage Pipeline
Allergan
  Late Stage Pipeline
Forest Laboratories
  Late Stage Pipeline
CSL Limited
  Late Stage Pipeline
UCB SA
  Late Stage Pipeline
Dainippon Sumitomo Pharma, Co., Ltd.
  Late Stage Pipeline
Shire
  Late Stage Pipeline
Biogen Idec
  Late Stage Pipeline
Watson
  Pipeline
Hospira
  Late Stage Pipeline
Lundbeck A/S
  Late Stage Pipeline
Kyowa Kirin
  Late Stage Pipeline
Warner Chilcott plc
  Late Stage Pipeline
Menarini Group
  Late Stage Pipeline
Valeant Pharmaceuticals
  Late Stage Pipeline
Purdue Pharma
  Late Stage Pipeline
Grifols SA
  Late Stage Pipeline
Shionogi & Co., Ltd.
  Late Stage Pipeline
Actelion
  Late Stage Pipeline
Ono Pharmaceutical Co.
  Late Stage Pipeline
Santen Pharmaceutical Co.
  Late Stage Pipeline
Reckitt Benckiser
  Late Stage Pipeline
Taisho Pharmaceutical Co.
  Late Stage Pipeline

CHAPTER SIX: MARKET FORECAST

Overview
Company Analysis
Pipeline Snapshot: Top 20 Companies
Market Trends and Value
Evaluating Changes in 2011 Market Value
Market Forecast
The Traditional Biotechnology Market
Biotechnology Market Facts and Forecast

APPENDIX: LIST OF COMPANIES

LIST OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY
Table 1-1: Global Pharmaceutical Market Forecast by Therapeutic Segment, 2016—based on late stage development projects evaluated
  Figure 1-1: Global Pharmaceutical Market Forecast by Therapeutic Segment, 2016—Potential Impact from Late-Stage Development
CHAPTER TWO: INTRODUCTION
Table 2-1: Total Healthcare Expenditures as a Percent of GDP by Country 1990, 2000 and 2009
  Figure 2-1: Total Healthcare Expenditures as a Percent of GDP by Country 1990, 2000, and 2009
  Table 2-2: Phases of Clinical Drug Development
  Table 2-3: Components of a Clinical Trial
  Figure 2-2: Biotechnology Approvals by Year Range (FDA)
CHAPTER THREE: ISSUES AND TRENDS
Table 3-1: International Population Trend Age 65+
  Table 3-2: United States Population Trend Age 65+
  Table 3-3: Recent Pharmaceutical Business Mergers and Acquisitions
  Table 3-4: Pharmaceutical/Biopharmaceutical R&D Statistics
  Table 3-5: Total Industry R&D Spending 2004-2010
CHAPTER FOUR: WORLDWIDE PHARMACEUTICAL INDUSTRY LEADERS
Table 4-1: Top Biopharmaceutical Companies, 1-20 by 2011 Sales
  Table 4-2: Pfizer’s Total Company Revenue and R&D Spending 2007-2011
  Figure 4-1: Pfizer’s Total Company Revenue and R&D Spending 2007-2011
  Table 4-3: Pfizer’s Late Stage Product Pipeline
  Figure 4-2: Pfizer’s Late Stage Product Pipeline by Therapeutic Area
  Table 4-4: Merck’s* Total Company Revenue and R&D Spending 2007-2011
  Table 4-5: Merck’s Late Stage Product Pipeline
  Table 4-5 (continued): Merck’s Late Stage Product Pipeline
  Figure 4-4: Merck’s Late Stage Product Pipeline by Therapeutic Area
  Table 4-6: Novartis’ Total Company Revenue and R&D Spending 2007-2011
  Table 4-7: Novartis’ Late Stage Product Pipeline
  Figure 4-7: Novartis’ Late Stage Product Pipeline by Therapeutic Area
  Table 4-8: Sanofi’s Total Company Revenue and R&D Spending 2007-2011
  Table 4-9: Sanofi-Aventis’ Late Stage Product Pipeline
  Figure 4-8: Sanofi Aventis’ Late Stage Product Pipeline by Therapeutic Area
  Table 4-10: Roche’s Total Company Revenue and R&D Spending 2007-2011
  Table 4-11: Roche’s Late Stage Product Pipeline
  Figure 4-10: Roche’s Late Stage Product Pipeline by Therapeutic Area
  Table 4-12: GlaxoSmithKline’s Total Company Revenue and R&D Spending 2007-2011
  Table 4-13: GlaxoSmithKline’s Late Stage Product Pipeline
  Figure 4-12: GlaxoSmithKline’s Late Stage Product Pipeline by Therapeutic Area
  Table 4-14: AstraZeneca’s Total Company Revenue and R&D Spending 2007-2011
  Table 4-15: AstraZeneca’s Late Stage Product Pipeline
  Figure 4-14: AstraZeneca’ Late Stage Product Pipeline by Therapeutic Area
  Table 4-16: Johnson & Johnson’s Total Company Revenue and R&D Spending 2007-2011
  Table 4-17: Johnson & Johnson’s Late Stage Product Pipeline
  Table 4-18: Eli Lilly’s Total Company Revenue and R&D Spending 2007-2011
  Table 4-19: Eli Lilly’s Late Stage Product Pipeline
  Figure 4-18: Eli Lilly & Co.’s Late Stage Product Pipeline by Therapeutic Area
  Table 4-20: Abbott’s Total Company Revenue and R&D Spending 2007-2011
  Table 4-21: Abbott’s Late Stage Product Pipeline
  Figure 4-20: Abbott’s Late Stage Product Pipeline by Therapeutic Area
  Table 4-22: Bristol-Myers Squibb’s Total Company Revenue and R&D Spending 2007-2011
  Table 4-23: Bristol-Myers Squibb’s Late Stage Product Pipeline
  Table 4-23: Bristol-Myers Squibb’s Late Stage Product Pipeline
  Figure 4-22: Bristol-Myers’ Late Stage Product Pipeline by Therapeutic Area
  Table 4-24: Takeda’s Total Company Revenue* and R&D Spending 2007-2011
  Table 4-25: Takeda Pharmaceutical’s Late Stage Product Pipeline
  Figure 4-24: Takeda Pharmaceutical’s Late Stage Product Pipeline by Therapeutic Area
  Table 4-26: TEVA’s Total Company Revenue and R&D Spending 2007-2011
  Table 4-27: TEVA’s Late Stage Product Pipeline
  Figure 4-26: TEVA’s Late Stage Product Pipeline by Therapeutic Area
  Table 4-28: Amgen’s Total Company Revenue and R&D Spending 2007-2011
  Table 4-29: Amgen’s Late Stage Product Pipeline
  Figure 4-28: Amgen’s Late Stage Product Pipeline by Therapeutic Area
  Table 4-30: Boehringer Ingelheim’s Total Company Revenue and R&D Spending 2007-2011
  Table 4-31: Boehringer Ingelheim’s Late Stage Product Pipeline
  Figure 4-30: Boehringer Ingelheim’s Late Stage Product Pipeline by Therapeutic Area
  Table 4-32: Bayer’s Total Company Revenue and R&D Spending 2007-2011
  Table 4-33: Bayer’s Late Stage Product Pipeline
  Figure 4-32: Bayers’ Late Stage Product Pipeline by Therapeutic Area
  Table 4-34: Novo Nordisk’s Total Company Revenue and R&D Spending 2007-2011
  Table 4-35: Novo Nordisk’s Late Stage Product Pipeline
  Figure 4-34: Novo Nordisk’s Late Stage Product Pipeline by Therapeutic Area
  Table 4-36: Astellas’ Total Company Revenue and R&D Spending 2007-2011
  Table 4-37: Astellas’ Late Stage Product Pipeline
  Figure 4-36: Astellas’ Late Stage Product Pipeline by Therapeutic Area
  Table 4-38: Daiichi Sankyo’s Total Company Revenue and R&D Spending 2007-2011
  Table 4-39: Daiichi Sankyo’s Late Stage Product Pipeline
  Figure 4-38: Daiichi Sankyo’s Late Stage Product Pipeline by Therapeutic Area
  Table 4-40: Otsuka Holding’s Total Company Revenue and R&D Spending 2007-2011
  Table 4-41: Otsuka Pharmaceutical’s Late Stage Product Pipeline
  Figure 4-40: Otsuka Pharmaceutical’s Late Stage Product Pipeline by Therapeutic Area
CHAPTER FIVE: COMPANIES OF INTEREST
Table 5-1: Top Biopharmaceutical Companies, 21-50 by 2011 Sales
  Table 5-2: Merck KGaA’s Late Stage Product Pipeline
  Table 5-3: Gilead Sciences’ Late Stage Product Pipeline
  Table 5-4: Eisai’s Late Stage Product Pipeline
  Table 5-5: Celgene’s Late Stage Product Pipeline
  Table 5-6: Mitsubishi Tanabe’s Late Stage Product Pipeline
  Table 5-7: Allergan’s Late Stage Product Pipeline
  Table 5-8: Forest Laboratories’ Late Stage Product Pipeline
  Table 5-9: UCB Pharma’s Late Stage Product Pipeline
  Table 5-10: Dainippon Sumitomo’s Late Stage Product Pipeline
  Table 5-11: Shire’s Late Stage Product Pipeline
  Table 5-12: Biogen Idec’s Late Stage Product Pipeline
  Table 5-13: Hospira’s Late Stage Product Pipeline
  Table 5-14: Lundbeck’s Late Stage Product Pipeline
  Table 5-15: Kyowa Kirin’s Late Stage Product Pipeline
  Table 5-16: Menarini’s Late Stage Product Pipeline
  Table 5-17: Valeant’s Late Stage Product Pipeline
  Table 5-18: Shionogi’s Late Stage Product Pipeline
  Table 5-19: Actelion’s Late Stage Product Pipeline
  Table 5-20: Ono Pharmaceutical’s Late Stage Product Pipeline
  Table 5-21: Santen’s Late Stage Product Pipeline
  Table 5-22: Taisho’s Late Stage Product Pipeline
CHAPTER SIX: MARKET FORECAST
Table 6-1: Top Biopharmaceutical Companies, 1-50 by 2011 Sales
  Table 6-1 (Continued): Top Pharmaceutical/Biopharmaceutical Companies, 1-50 by 2011 Sales
  Table 6-2: Company Pipelines by Total Late Stage Development Projects
  (Top 20 Companies by Revenues)
  Figure 6-1: Company Pipelines by Total Late Stage Development Projects (Top 20 Companies by Revenues)
  Table 6-3: Global Pharmaceutical Market Value by Therapeutic Segment, 2005-2010
  Figure 6-2: Global Pharmaceutical Market Value by Therapeutic Segment, 2005-2010
  Table 6-4: Global Pharmaceutical Market Value by Therapeutic Segment, 2010 vs. 2011
  Figure 6-3: Global Pharmaceutical Market Value by Therapeutic Segment, 2010 vs. 2011
  Table 6-5: Global Pharmaceutical Market Forecast by Therapeutic Segment, 2016—based on late stage development projects evaluated
  Figure 6-4: Global Pharmaceutical Market Forecast by Therapeutic Segment, 2016—based on late stage development projects evaluated
  Figure 6-5: Global Pharmaceutical Market Forecast by Therapeutic Segment, 2016—Potential Impact from Late-Stage Development
  Figure 6-6: Global Pharmaceutical Market Forecast by, 2016—Potential Impact from Late-Stage Development
  Table 6-6: Top 5 Biotechnology Companies*, 2011 Sales
  Table 6-7: Top 10 Biotechnology and Pharmaceutical Products, by 2011 Revenues
  Figure 6-7: Top 10 Biotechnology and Pharmaceutical Products, by 2011 Revnues